GUANIDINE HYDROCHLORIDE
LOE ApproachingNDAORALTABLET
Approved
Oct 1939
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Guanidine hydrochloride is an oral small-molecule tablet approved in 1939 by Merck & Co. The mechanism of action and specific indications are not publicly documented in available records. This is a legacy product with a long commercial history but limited current clinical development activity.
LOE Approaching
Loss-of-exclusivity is imminent; expect declining team size and shift toward generic transition planning and lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on guanidine hydrochloride offers limited long-term career growth due to imminent loss of exclusivity and negligible current commercial activity. Positions on this product are typically focused on managed decline, regulatory compliance, and transition planning rather than innovation or expansion.
Brand ManagerCommercial Analyst
Worked on GUANIDINE HYDROCHLORIDE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.